Stay Updated with the Latest Sanofi SNY News in Real Time
Find SNY news now at Meyka AI. Stay informed with the latest Sanofi stocks updates, including price news, market analysis, and expert insights.
European Markets: FTSE 100 Gains 0.26%, CAC 40 Climbs 0.30% as Geopolitical Risks Remain in Focus
FTSE 100 edged higher on July 6 as European equities opened the week with cautious gains despite ongoing geopolitical concerns. The UK’s benchmark index rose 0.26%, while France’s CAC 40 advanced 0.30% during early trading. Germany’s DAX also traded modestly higher as investors monitored developments in the Middle East, global trade discussions, and expectations for…
GV.PA Stock Surges 5.88% on Heavy Trading Volume Today
Genomic Vision SA (GV.PA) gains 5.88% with 38.5M shares traded on EURONEXT. Healthcare diagnostics stock shows intraday strength.
ALINT.PA stock surges 45% on high volume trading May 8
ALINT.PA stock jumps 45% with 86,552 shares traded. IntegraGen SA genomics services drive volume surge on EURONEXT.
BNTX BioNTech SE Earnings: Beat EPS, Missed Revenue
BioNTech beat EPS by 3.72% but missed revenue by 34.22%. Q1 2026 earnings show mixed results for the biotech company.
22UA.F BioNTech SE Earnings Beat EPS, Misses Revenue
BioNTech SE (22UA.F) beat EPS estimates by 11.24% but missed revenue by 34.22% in Q1 2026 earnings.
SGMO Stock Surges 31.5% as Sangamo Therapeutics Nears May 11 Earnings
SGMO stock jumped 31.5% to $0.1776 on May 5, 2026. Sangamo Therapeutics reports Q1 earnings Monday with analyst expectations of $0.0050 EPS.
RVMD Earnings Preview: Revolution Medicines Reports May 6
Revolution Medicines (RVMD) reports Q1 earnings May 6. Analysts expect -$1.83 EPS and $2.42M revenue. Stock up 6% ahead of release.
ALNY Earnings Beat: Alnylam Crushes Q1 2026 Estimates
Alnylam Pharmaceuticals (ALNY) crushed Q1 2026 earnings with EPS of $1.51 vs $0.90 estimate, up 68.72%. Revenue hit $1.17B, beating by 4.63%.
SAP.DE Stock Slides 0.26% on May 1 as AI Demand Shifts
SAP.DE trades at €145.50 on XETRA, down 0.26% intraday. Enterprise software leader faces headwinds despite strong fundamentals and B+ grade.